Table of Contents Author Guidelines Submit a Manuscript
Case Report
Case Reports in Infectious Diseases
Volume 2019, Article ID 8314349, 1 page
https://doi.org/10.1155/2019/8314349
Corrigendum

Corrigendum to “In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways”

1University of Houston College of Pharmacy, Houston, TX, USA
2Molecular Genetics and Antimicrobial Resistance Unit, International Center for Microbial Genomics, Universidad El Bosque, Bogotá, Colombia
3Center for Antimicrobial Resistance and Microbial Genomics, UTHealth McGovern Medical School, Houston, TX, USA
4Millennium Initiative for Collaborative Research on Bacterial Resistance (MICROB-R), Santiago, Chile
5Grupo de Investigación en Resistencia Antimicrobiana y Epidemiología Hospitalaria–RAEH, Universidad El Bosque, Bogotá, Colombia
6Division of Infectious Diseases, UTHealth McGovern Medical School, Houston, TX, USA
7Genomics and Resistant Microbes Group, Facultad de Medicina Clinica Alemana, Universidad del Desarrollo, Santiago, Chile
8Department of Microbiology and Molecular Genetics, UTHealth McGovern Medical School, Houston, TX, USA
9Center for Infectious Diseases, University of Texas School of Public Health, Houston, TX, USA

Correspondence should be addressed to Truc T. Tran; ude.cmt.htu@nart.t.curt

Received 4 March 2019; Accepted 12 March 2019; Published 2 September 2019

Copyright © 2019 Erik Skoglund et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


In the article titled “In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways” [1], a grant number was missing. The Acknowledgments section should be updated as follows.

We thank Morouge Alramadhan for technical support. We also thank the Universidad El Bosque for financial support for whole genome sequencing (Grant no. PCI-2017-9447). This work was supported by the National Institutes of Health (Grant nos. K08-AI113317 (TTT) and K24-AI121296 (CAA)), the Millennium Science Initiative of the Ministry of Economy, Development and Tourism, Government of Chile (JMM), and the Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT), FONDECYT 1171805, Ministry of Education, Government of Chile (JMM).

References

  1. E. Skoglund, H. Abodakpi, R. Rios et al., “In Vivo resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa arising by ampC- and non-ampC-mediated Pathways,” Case Reports in Infectious Diseases, vol. 2018, Article ID 9095203, 4 pages, 2018. View at Publisher · View at Google Scholar